Change of preoperative symptoms of the late-onset hypogonadism syndrome after robot-assisted radical prostatectomy.
Aging male symptoms
Late-onset hypogonadism
Prostate cancer
Robot-assisted radical prostatectomy
Testosterone
Journal
Current urology
ISSN: 1661-7649
Titre abrégé: Curr Urol
Pays: United States
ID NLM: 101471188
Informations de publication
Date de publication:
Jun 2021
Jun 2021
Historique:
received:
28
03
2020
accepted:
11
06
2020
entrez:
25
6
2021
pubmed:
26
6
2021
medline:
26
6
2021
Statut:
ppublish
Résumé
As prostate cancer (PCa) is a common cancer among older men, patients with PCa often show aging male symptoms (AMSs). This study aimed to investigate the preoperative AMSs of the late-onset hypogonadism (LOH) syndrome and the effects on them after robot-assisted radical prostatectomy (RARP). One hundred eighty-eight patients who underwent RARP without androgen deprivation therapy were measured for serum free and serum total testosterone, and were preoperatively assessed for symptoms of the LOH syndrome using a questionnaire containing an AMS score. Patients with a preoperative AMS score higher than 37 and a serum free testosterone level lower than 8.5 pg/mL were classified as Group A, with the remaining classified as Group B. AMS scores were measured at 1, 3, 6, 9, and 12 months after surgery. Of the 188 patients, 49 and 139 patients were classified as Groups A and B, respectively. Preoperative AMS scores were 44.5 ± 8.2 in Group A and 28.6 ± 5.3 in Group B ( Our results indicate that AMSs in PCa patients with the LOH syndrome can expect the same level of improvement as patients without it.
Sections du résumé
BACKGROUND
BACKGROUND
As prostate cancer (PCa) is a common cancer among older men, patients with PCa often show aging male symptoms (AMSs). This study aimed to investigate the preoperative AMSs of the late-onset hypogonadism (LOH) syndrome and the effects on them after robot-assisted radical prostatectomy (RARP).
MATERIALS AND METHODS
METHODS
One hundred eighty-eight patients who underwent RARP without androgen deprivation therapy were measured for serum free and serum total testosterone, and were preoperatively assessed for symptoms of the LOH syndrome using a questionnaire containing an AMS score. Patients with a preoperative AMS score higher than 37 and a serum free testosterone level lower than 8.5 pg/mL were classified as Group A, with the remaining classified as Group B. AMS scores were measured at 1, 3, 6, 9, and 12 months after surgery.
RESULTS
RESULTS
Of the 188 patients, 49 and 139 patients were classified as Groups A and B, respectively. Preoperative AMS scores were 44.5 ± 8.2 in Group A and 28.6 ± 5.3 in Group B (
CONCLUSIONS
CONCLUSIONS
Our results indicate that AMSs in PCa patients with the LOH syndrome can expect the same level of improvement as patients without it.
Identifiants
pubmed: 34168525
doi: 10.1097/CU9.0000000000000020
pii: Curr-Urol-21-0069
pmc: PMC8221015
doi:
Types de publication
Journal Article
Langues
eng
Pagination
85-90Informations de copyright
Copyright © 2021 The Authors. Published by Wolters Kluwer Health, Inc.
Déclaration de conflit d'intérêts
No conflict of interest has been declared by the author.
Références
J Urol. 2000 Mar;163(3):824-7
pubmed: 10687985
Nat Rev Urol. 2011 Apr 19;8(6):335-44
pubmed: 21502974
J Clin Endocrinol Metab. 2001 Feb;86(2):724-31
pubmed: 11158037
Health Qual Life Outcomes. 2003 May 01;1:15
pubmed: 12747807
N Engl J Med. 2012 Mar 15;366(11):981-90
pubmed: 22417251
Urology. 1999 Sep;54(3):509-16
pubmed: 10475363
BJU Int. 2020 Jul;126(1):91-96
pubmed: 32124531
Prostate. 2001 Apr;47(1):52-8
pubmed: 11304729
Eur Urol. 2013 Oct;64(4):672-9
pubmed: 23587870
Urology. 2006 Dec;68(6):1263-7
pubmed: 17169647
Andrology. 2020 Nov;8(6):1606-1613
pubmed: 32056383
J Clin Lab Anal. 2017 Sep;31(5):
pubmed: 27714896
Biomed Res Int. 2017;2017:9615080
pubmed: 28261619
Nihon Hinyokika Gakkai Zasshi. 2004 Sep;95(6):751-60
pubmed: 15508699
Eur Urol. 2012 Sep;62(3):418-30
pubmed: 22749850
Eur Urol. 2018 May;73(5):664-671
pubmed: 29273404
JAMA. 1995 Jan 11;273(2):129-35
pubmed: 7799493
N Engl J Med. 2016 Oct 13;375(15):1415-1424
pubmed: 27626136
Eur Urol. 2012 Sep;62(3):405-17
pubmed: 22749852
Cancer. 1997 May 15;79(10):1977-86
pubmed: 9149026